Nomura/Instinet Reiterates Buy on Biogen (BIIB) Following Announced IONS Collaboration
Tweet Send to a Friend
Nomura/Instinet reiterated a Buy rating and $420.00 price target on Biogen (NASDAQ: BIIB) following the company's announced details of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
